Document is current
Any future updates will be listed below
-
Authors
Schlam, Ilana
Smith, D. Max
Peer, Cody
Sissung, Tristan
Schmidt, Keith T.
Tan, Ming
Chitalia, Ami
Bishopric, Nanette H.
Steinberg, Seth
Choo-Wosoba, Hyoyoung
Napoli, Giulia
Gallagher, Christopher https://orcid.org/0000-0002-3846-5052
Ashai, Nadia
Whitaker, Kristen
Mainor, Candace
Tiwari, Shruti
Swanson, Nicole
Malloy, Stacy
Isaacs, Claudine https://orcid.org/0000-0002-9646-1260
Figg, William Douglas
Swain, Sandra M. https://orcid.org/0000-0002-1320-3830
-
Funding
Funding for this research was provided by:
Breast Cancer Research Foundation (BCRF-20-156)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (Core grant (P30CA051008), Grant # UL1TR000101 (previously UL1RR031975), Core grant (P30CA051008), Grant # UL1TR000101 (previously UL1RR031975))
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences
Conquer Cancer Foundation (ASCO Young Investigator Award (PI))
- License Information
-
More Information
Article History
Received: 28 June 2024
Accepted: 14 September 2024
First Online: 30 September 2024
Competing interests
: D.M.S. reports research funding to institution from Kailos Genetics, Inc. MTT reports receiving honoria from AstraZeneca, Incyce, Otsuka, Sanofi Pasteur, consulting for American Gene Technologies, and receiving research funding to institution from Genentech. N.H.B. reports they or an immediate family member have consulted for Catena, a leadership role for Seagen, stock or ownership in Seagen, Lilly, Gilead Sciences, and Pfizer. C.G. reports consulting for Daiichi Sankyo, Illy, Biotheranostics, and Pfizer and Speakers’ Bureau for Daiichi Sankyo/UCB Japan. K.D.W. reports consults for Biotheranostics and receiving honoraria from MHJ Life Sciences. C.B.M. reports receiving research funding to institution from Pfizer and Cantex Pharmaceuticals. C.I. reports consulting for Pfizer, Novartis, Puma Biotechnology, Seagen, Ion Solutions, AstraZeneca/MedImmune, Gilead Sciences, receiving travel support from Pfizer, holding patents, royalties, or other intellectual property from McGraw Hill Publishing, UpToDate (Wolters Kluwer), Elsevier, receiving honoraria from Pfizer, receiving research funding to institution from Tesaro, Merck, Seagen, Pfizer, GlaxoSmithKline, AstraZeneca, Novartis, Genentech/Rosche, Bristol-Myers Squibb/Celgene, and other relationships with Side-Out Foundation, M.J.H./P.E.R., Curio/Vaniam Group, and Medscape. W.D.F. reports research funding to institution from Celgene, Astellas Pharma, Nerviano Medical Sciences, Pfizer, NovaRX, TRACON Pharma, Biocompatibles, and Propella Therapeutics. SM Swain reports consulting for Genetech/Roche, Daiichi Sankyo, Molecular Templates, AstraZeneca, Aventis Pharma, Jaguar Health, a leadership role at Seagen, receiving travel support from Daiichi Sankyo, Aventis Pharma, Genentech/Roche, and Chugai/Roche, stock or ownership in Seagen, receiving honoraria from Chugai/Roche, and other relationships with Roche, AstraZeneca, and Genentech/Roche. I.S., C.P., T.S., K.T.S., A.C., S.S., H.C.W., N.A., S.R.T., N.S., G.C.N., S.K.M.: Nothing to declare.
